NASDAQ:LXRX Lexicon Pharmaceuticals - LXRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.31 -0.01 (-0.43%) (As of 03/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.29▼$2.3850-Day Range$2.17▼$2.6852-Week Range$1.31▼$3.48Volume289,635 shsAverage Volume530,014 shsMarket Capitalization$435.97 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Lexicon Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside376.2% Upside$11.00 Price TargetShort InterestBearish2.10% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.57) to ($0.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.84 out of 5 starsMedical Sector569th out of 995 stocksPharmaceutical Preparations Industry270th out of 482 stocks 3.3 Analyst's Opinion Consensus RatingLexicon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Lexicon Pharmaceuticals has a forecasted upside of 376.2% from its current price of $2.31.Amount of Analyst CoverageLexicon Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.10% of the outstanding shares of Lexicon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverLexicon Pharmaceuticals has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Lexicon Pharmaceuticals has recently increased by 4.20%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLexicon Pharmaceuticals does not currently pay a dividend.Dividend GrowthLexicon Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LXRX. Previous Next 3.3 News and Social Media Coverage News SentimentLexicon Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Lexicon Pharmaceuticals this week, compared to 1 article on an average week.Search Interest16 people have searched for LXRX on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Lexicon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lexicon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.50% of the stock of Lexicon Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lexicon Pharmaceuticals are expected to grow in the coming year, from ($0.57) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexicon Pharmaceuticals is -3.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexicon Pharmaceuticals is -3.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexicon Pharmaceuticals has a P/B Ratio of 3.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lexicon Pharmaceuticals (NASDAQ:LXRX) StockLexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.Read More Receive LXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address LXRX Stock News HeadlinesMarch 8, 2023 | msn.comLexicon Pharmaceuticals's Return On Capital Employed InsightsMarch 8, 2023 | msn.comJefferies Initiates Coverage of Lexicon Pharmaceuticals (LXRX) with Hold RecommendationMarch 28, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 7, 2023 | msn.comLexicon initiated at buy at Jefferies on uptake of heart failure candidate sotagliflozinMarch 4, 2023 | finance.yahoo.comLexicon Reveals “INTO THE DARK” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following HospitalizationMarch 4, 2023 | finance.yahoo.comNew Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of CardiologyMarch 3, 2023 | marketwatch.comLexicon Pharmaceuticals Stock Jumps on 4Q Revenue, Sotagliflozin Heart Drug UpdateMarch 2, 2023 | msn.comLexicon Pharmaceuticals GAAP EPS of -$0.16 misses by $0.03, revenue of $0.03M misses by $0.02MMarch 28, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 2, 2023 | finance.yahoo.comLexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business UpdateMarch 1, 2023 | msn.comEarnings Preview For Lexicon PharmaceuticalsMarch 1, 2023 | finance.yahoo.comLexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023February 22, 2023 | thestreet.comLexicon Shares Soar After Success in Late-Stage Cancer Drug TrialFebruary 20, 2023 | finance.yahoo.comNew Analyses of Sotagliflozin to Be Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of CardiologyFebruary 1, 2023 | finance.yahoo.comLexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) largest shareholders are private equity firms with 48% ownership, institutions own 26%January 6, 2023 | finance.yahoo.comLexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare ConferenceDecember 22, 2022 | finance.yahoo.comLexicon Pharma's Pain Candidate Fails In Postherpetic Neuralgia StudyDecember 21, 2022 | marketwatch.comLexicon Pharmaceuticals Shares Drop 11% on LX9211 Study ResultsDecember 21, 2022 | finance.yahoo.comLexicon Announces Topline Results From Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic NeuralgiaDecember 14, 2022 | msn.comLexicon Pharmaceuticals's Return On Capital Employed OverviewNovember 28, 2022 | finance.yahoo.comLexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx ConferenceNovember 15, 2022 | finance.yahoo.comLexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics SummitNovember 12, 2022 | finance.yahoo.comLexicon Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 11, 2022 | finance.yahoo.comLexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare ConferenceNovember 10, 2022 | markets.businessinsider.comLexicon Pharmaceuticals (LXRX) Gets a Hold from NeedhamNovember 10, 2022 | seekingalpha.comLexicon Pharmaceuticals, Inc. (LXRX) Q3 2022 Earnings Call TranscriptNovember 9, 2022 | finance.yahoo.comLexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business UpdateSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address LXRX Company Calendar Last Earnings11/03/2021Today3/28/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:LXRX Previous SymbolNASDAQ:LEXG CUSIP52887210 CIK1062822 Webwww.lexpharma.com Phone(281) 863-3000Fax281-863-8010Employees87Year Founded1995Price Target and Rating Average Stock Price Forecast$11.00 High Stock Price Forecast$20.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+181.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,940,000.00 Net Margins-73,341.00% Pretax Margin-73,341.01% Return on Equity-96.02% Return on Assets-64.27% Debt Debt-to-Equity Ratio0.41 Current Ratio6.08 Quick Ratio6.08 Sales & Book Value Annual Sales$140,000.00 Price / Sales3,114.05 Cash FlowN/A Price / Cash FlowN/A Book Value$0.62 per share Price / Book3.73Miscellaneous Outstanding Shares188,730,000Free Float176,459,000Market Cap$435.97 million OptionableOptionable Beta1.32 Social Links Key ExecutivesLonnel CoatsChief Executive Officer & DirectorJeffrey L. WadePresident & Chief Financial OfficerCraig B. GranowitzChief Medical Officer & Senior Vice PresidentBrian T. CrumSecretary, Senior Vice President & General CounselKiernan A. SethChief Commercial Officer & Vice PresidentKey CompetitorsEmergent BioSolutionsNYSE:EBSVanda PharmaceuticalsNASDAQ:VNDARigel PharmaceuticalsNASDAQ:RIGLIntercept PharmaceuticalsNASDAQ:ICPTXOMANASDAQ:XOMAView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 18,221 shares on 3/23/2023Ownership: 0.012%Alliancebernstein L.P.Bought 4,800 shares on 2/16/2023Ownership: 0.048%Morgan StanleySold 33,241 shares on 2/15/2023Ownership: 0.072%Squarepoint Ops LLCBought 27,264 shares on 2/15/2023Ownership: 0.014%MetLife Investment Management LLCSold 18,221 shares on 2/15/2023Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions LXRX Stock - Frequently Asked Questions Should I buy or sell Lexicon Pharmaceuticals stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LXRX shares. View LXRX analyst ratings or view top-rated stocks. What is Lexicon Pharmaceuticals' stock price forecast for 2023? 3 Wall Street research analysts have issued 1 year price targets for Lexicon Pharmaceuticals' stock. Their LXRX share price forecasts range from $3.00 to $20.00. On average, they anticipate the company's share price to reach $11.00 in the next year. This suggests a possible upside of 376.2% from the stock's current price. View analysts price targets for LXRX or view top-rated stocks among Wall Street analysts. How have LXRX shares performed in 2023? Lexicon Pharmaceuticals' stock was trading at $1.91 at the beginning of the year. Since then, LXRX shares have increased by 20.9% and is now trading at $2.31. View the best growth stocks for 2023 here. When is Lexicon Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our LXRX earnings forecast. How were Lexicon Pharmaceuticals' earnings last quarter? Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02. The biopharmaceutical company had revenue of $0.02 million for the quarter. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 96.02% and a negative net margin of 73,341.00%. During the same quarter in the previous year, the firm earned $0.71 earnings per share. What ETFs hold Lexicon Pharmaceuticals' stock? ETFs with the largest weight of Lexicon Pharmaceuticals (NASDAQ:LXRX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB) and What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO? 9 employees have rated Lexicon Pharmaceuticals Chief Executive Officer Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among the company's employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Lexicon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD). What is Lexicon Pharmaceuticals' stock symbol? Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX." Who are Lexicon Pharmaceuticals' major shareholders? Lexicon Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (1.74%), Pinnacle Associates Ltd. (1.05%), Pinnacle Associates Ltd. (1.02%), Geode Capital Management LLC (0.85%), Point72 Asset Management L.P. (0.71%) and Millennium Management LLC (0.62%). Insiders that own company stock include International SCA Artal and James F Tessmer. View institutional ownership trends. How do I buy shares of Lexicon Pharmaceuticals? Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lexicon Pharmaceuticals' stock price today? One share of LXRX stock can currently be purchased for approximately $2.31. How much money does Lexicon Pharmaceuticals make? Lexicon Pharmaceuticals (NASDAQ:LXRX) has a market capitalization of $435.97 million and generates $140,000.00 in revenue each year. The biopharmaceutical company earns $-101,940,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. How can I contact Lexicon Pharmaceuticals? Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The official website for the company is www.lexpharma.com. The biopharmaceutical company can be reached via phone at (281) 863-3000, via email at cschultz@lexpharma.com, or via fax at 281-863-8010. This page (NASDAQ:LXRX) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.